Claims for Patent: 10,406,224
✉ Email this page to a colleague
Summary for Patent: 10,406,224
Title: | Nanoparticle complexes of paclitaxel, trastuzumab, and albumin |
Abstract: | Described are stable nanoparticle complexes of 100 nm to 900 nm comprising paclitaxel, albumin and an antibody. The nanoparticle complexes are suitable for the treatment of cancer. |
Inventor(s): | Markovic; Svetomir N. (Rochester, MN), Nevala; Wendy K. (Rochester, MN) |
Assignee: | Mayo Foundation for Medical Education and Research (Rochester, MN) |
Application Number: | 15/052,623 |
Patent Claims: | 1. An antibody-albumin nanoparticle complex comprising albumin, a trastuzumab antibody, and a therapeutically effective amount of paclitaxel, wherein the nanoparticle
complex has been pre-formed in vitro by mixing an aqueous albumin-paclitaxel nanoparticle with the antibody under conditions to form the nanoparticle complex, such that the antibody portion of said complex retains HER2 binding specificity, wherein the
complex has a diameter of between 0.1 .mu.m and 1 .mu.m.
2. The antibody-albumin nanoparticle complex of claim 1, said complex having a diameter between 0.1 .mu.m and 0.9 .mu.m. 3. The antibody-albumin nanoparticle complex of claim 1, said complex having a diameter of between 0.1 .mu.m and 0.3 .mu.m. 4. The antibody-albumin nanoparticle complex of claim 1, wherein the ratio of albumin-paclitaxel nanoparticle to antibody is between 5:1 and 1:2.5. 5. The antibody-albumin nanoparticle complex of claim 1, wherein said nanoparticle complex comprises an alkylating agent. 6. The antibody-albumin nanoparticle complex of claim 5, wherein said alkylating agent is a platinum compound. 7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of antibody-albumin nanoparticle complexes, said nanoparticle complexes comprising albumin, a trastuzumab antibody, and a therapeutically effective amount of paclitaxel, wherein the nanoparticle complexes have been pre-formed in vitro by mixing aqueous albumin-paclitaxel nanoparticles with the antibody under conditions to form the nanoparticle complexes, such that the antibody retains HER2 binding specificity, wherein the average diameter of at least 90 percent of said complexes is between 0.1 .mu.m and 1 .mu.m. 8. The pharmaceutical composition of claim 7, wherein the average diameter of at least 90 percent of said complexes is between 0.1 .mu.m and 0.9 .mu.m. 9. The pharmaceutical composition of claim 7, wherein the average diameter of said complexes is between 0.1 .mu.m and 0.3 .mu.m. 10. The pharmaceutical composition of claim 7, wherein the ratio of albumin-paclitaxel nanoparticle to antibody is between 5:1 and 1:2.5. 11. The pharmaceutical composition of claim 7, wherein said composition comprises an alkylating agent. 12. The pharmaceutical composition of claim 11, wherein said alkylating agent is a platinum compound. 13. The pharmaceutical composition of claim 7 which is formulated for injection. 14. The pharmaceutical composition of claim 7, wherein the pharmaceutically acceptable carrier is saline, water, lactic acid, mannitol, or a combination thereof. |
Details for Patent 10,406,224
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2032-10-01 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2032-10-01 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2032-10-01 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.